Experience with intermediate-dose (110–120 mg/m2) epirubicin

T. Hickish,D. Cunningham,A. Haydock,R. Coombes
DOI: https://doi.org/10.1007/BF00254108
Cancer Chemotherapy and Pharmacology
Abstract:
What problem does this paper attempt to address?